Shenzhen Neptunus Bioengineering Co (000078) Fair Value & Analysis
Healthcare · CN · Market cap 4.2B CNY
Analysis
Shenzhen Neptunus Bioengineering Co (000078) currently trades at ¥1.45, while our model-based Fair Value estimate is ¥0.9500 — implying the stock looks roughly 34.5% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors. In addition, the company provides drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. It develops HW130 injection that completed the Phase I clinical trial for anti-tumor; and NEP018 for anti-tumor. Shenz…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.